Project Grant HT9425261E266
Award Date 9/1/26
Completion Date 8/31/29
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Irvine, CA 92697, USA
Similar Awards
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded the University of California Irvine a $747,092 Project Grant effective September 1, 2026, through August 31, 2029, under the Military Medical Research and Development program (CFDA 12.420). The project, titled "Immune Checkpoint Inhibition-Related Cognitive Impairments: Mechanisms and Mitigation," supports basic and applied biomedical research investigating cognitive side effects associated with immunotherapy...
- Federal Grant Award Summary The Defense Health Agency awarded a $559,976 Project Grant to the University of California Irvine, effective September 1, 2026, through August 31, 2028, under the Military Medical Research and Development program (CFDA 12.420). The project, "Targeting Mechanosensing PIEZO1 Channels of CD8 T Cells to Improve Melanoma Tumor Immunity," supports basic and applied biomedical research addressing Service Member health priorities. The research focuses on...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $750,000 Project Grant to the University of California Irvine on May 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) for the project "A Novel Strategy to Improve the Effectiveness of Radiation Therapy in Breast Cancer." The three-year award period runs through April 30, 2029, and supports investigator-initiated biomedical research addressing medical challenges relevant to Service...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $1,197,813 Project Grant to the University of California, San Diego on August 15, 2025, under the Military Medical Research and Development program (CFDA 12.420) for mechanism dissection and model development of human PD1 (Programmed Death receptor 1) in melanoma. The three-year award, with a completion date of August 14, 2028, supports basic and applied biomedical research investigating immunotherapeutic mechanisms relevant...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded the University of California, Davis a $1.7M Project Grant under the Military Medical Research and Development program (CFDA 12.420) for a three-year research initiative running September 1, 2026, through August 31, 2029. The grant supports a novel therapeutic approach to address chemotherapy-induced peripheral neuropathy (CIPN) in prostate cancer patients by targeting soluble epoxide hydrolase (SEH) as a treatment mechanism....
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $1,197,884 to the University of California, San Diego (UCSD) under the Military Medical Research and Development program (CFDA 12.420) on August 15, 2025, for a three-year performance period extending through August 14, 2028. This project grant funds mechanism dissection and model development of human PD1 (Programmed Death Receptor 1) in melanoma, supporting basic and applied biomedical research aligned with DHA's...
- Federal Project Grant Award Summary The University of California, Irvine received a $785,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective June 15, 2025, with a completion date of June 14, 2028. The research project investigates an endocannabinoid deficit in brain neuroinflammatory control as a therapeutic target for Gulf War Illness. This three-year funded initiative supports hypothesis-driven biomedical...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded The Regents of the University of California, San Francisco a $1.4 million Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026, through July 31, 2029. The award supports investigator-initiated research into the metabolic mechanisms of resistance to mutant isocitrate dehydrogenase (IDH) inhibition in gliomas. This three-year research initiative will be conducted at...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded the University of California, Los Angeles a $590,625 Project Grant effective September 1, 2025, through August 31, 2028, under the Military Medical Research and Development program (CFDA 12.420). This pilot study investigates dual immunotherapy combining PD-1 and CD73 checkpoint inhibitors in combination with chemotherapy for treating pancreatic adenocarcinoma, with a focus on characterizing immune mechanisms of...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $235,476 project grant to the University of California, Los Angeles (UCLA) Office of Research Administration on November 1, 2025, to develop new cell-mediated immunotherapeutic strategies for neuroendocrine prostate cancer. The two-year award, which concludes October 31, 2027, is funded under the Military Medical Research and Development program (CFDA 12.420) and will be conducted at UCLA's Los Angeles, California facility....